ARWR — ARROWHEAD PHARMACEUTICALS

Ownership history in JOHNSON & JOHNSON  ·  17 quarters on record

This page tracks every 13F SEC filing in which JOHNSON & JOHNSON reported a position in ARROWHEAD PHARMACEUTICALS (ARWR). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
24.61% (2021 Q4)
Avg. % of fund
5.02%
First filed
2021 Q3
Last filed
2025 Q3
Quarters held
17
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 UNCHANGED 247,598 — 0% 1.70% $8.5M $34.49
2025 Q2 UNCHANGED 247,598 — 0% 1.19% $4.0M $15.80
2025 Q1 UNCHANGED 247,598 — 0% 0.92% $3.2M $12.74
2024 Q4 UNCHANGED 247,598 — 0% 1.21% $4.7M $18.80
13 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    ARWR price (monthly, adj. close)

Other funds also holding ARWR

As of 2025 Q4 — sorted by position size

Western Financial Corp/CA 3Y 21.6% Avoro Capital Advisors LLC 3Y 7Y 6.93% Privium Fund Management B.V. 3Y 4.87% M28 Capital Management LP 3Y 3.25% WEALTH EFFECTS LLC 3Y 2.98% Siren, L.L.C. 2.97% Slate Path Capital LP 3Y 7Y 2.26% Vestal Point Capital, LP 2.03% Exome Asset Management LLC 1.58% DEERFIELD MANAGEMENT COMPANY, L.P. 3Y 7Y 1.55%
← Back to JOHNSON & JOHNSON Holdings